Novo Nordisk Moves to Outbid Pfizer With Up to $9 Billion Offer for Obesity Drug Developer Metsera

Core Viewpoint - Novo Nordisk's proposal is currently under review by Metsera's board of directors [1] Company Summary - Novo Nordisk has submitted a proposal that is awaiting evaluation by the board of directors of Metsera [1]